Man claims he went blind after taking Ozempic, shares warning for other users
US study links GLP-1 drugs to rare vision loss
54 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 54 separate news trends connected to Glp-1 Drugs, spanning June 21, 2026 through October 15, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 425 article observations and 405 source signals, led by Health, Business, Entertainment coverage. Use it to compare how individual events emerged, spread and changed over time.
US study links GLP-1 drugs to rare vision loss
Obesity drugs are being repurposed to treat addiction and depression, sparking hopes for new treatments.
Over 15 million people in America take GLP-1 drugs, with a majority agreeing on a shared issue.
Doctors warn of potential fertility impact from GLP-1 drugs, sparking hope and concern among couples.
6 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
WHO advises against GLP-1 drugs for young children with obesity
Rare vision risk linked to GLP-1 drugs sparks concern
4 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Study finds link between GLP-1 drugs and nutritional deficiencies in children
10 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Weight loss drugs linked to fewer asthma attacks, study finds
Weight regain after obesity drugs spikes risk of suicidal thoughts, study finds
Investors in Novo Nordisk are on edge as the pharmaceutical giant faces increasing competition in the GLP-1 market.
Recent scientific findings reveal specific brain mechanisms and proteins influencing fatty food cravings and weight loss treatments.
Low‑dose GLP‑1 therapies may unlock weight loss with less drug, reshaping treatment standards
11 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Men’s weight‑loss drugs face a double‑edge of stigma and rebound fears as GLP‑1 use spikes.
Some companies are reconsidering their insurance policies for GLP-1 weight loss drugs, affecting employee benefits.
GLP-1 drugs, known for weight loss, may also reduce physical activity, sparking debate among health experts.
People with serious mental health conditions may soon have a new treatment option.
Millions of Medicare patients with qualifying diagnoses are excluded from a new GLP-1 discount program.
Doctors are exploring health benefits of GLP-1 drugs beyond weight loss, sparking debate on their potential as a 'fountain of youth'.
New research and drugs are challenging long-held beliefs about weight loss and obesity in the US.
A new weight loss drug may burn fat without the muscle loss seen in GLP-1 drugs.
A specific nutrient is gaining attention for its role in digestion and beyond, sparking interest in precision nutrition.
New research reveals both promising benefits and potential risks of GLP-1 weight loss drugs.
New research suggests that popular weight-loss drugs may work differently than previously understood.
The VA is launching a study to test GLP-1s for treating alcohol use disorder.
A popular diabetes drug may also protect against heart attacks, but the mechanism is still unclear.
GLP-1 drugs are transforming teen attitudes toward obesity and body image, driven by social media.
Chrissy Metz's public embrace of GLP-1 drugs after years of skepticism has sparked a wave of celebrity conversations about weight loss.
Medical discourse on GLP-1 medications is shifting beyond weight loss as new research highlights brain mechanisms and non-weight-related health outcomes.
Starbucks is the latest employer to end coverage of GLP-1 drugs for weight loss, as costs rise.
Bank of America's $250 million annual investment in weight loss drugs for employees is making headlines.
Amazon Pharmacy is now delivering GLP-1 weight-loss drugs to Medicare patients for $50 a month.
CVS Health is expanding access to weight-loss treatments through a new Eli Lilly partnership, resulting in an updated financial outlook for the company.
Eli Lilly's stock surges as demand for its weight-loss drugs continues to drive revenue growth.
Divergent earnings reports this week reveal a surge in pharmaceutical demand alongside cooling momentum in the digital advertising sector.
A study links popular GLP-1 drugs to vision loss, sparking concern among patients and optometrists.
A side effect of popular weight-loss drugs is causing patients to appear older.
Novo Nordisk's stock price drops despite beating earnings forecasts, as investors react to revised guidance.
GLP-1 drugs are linked to a decline in obesity, but doctors are raising alarms about misuse.
Six outlets report that the FDA is scrutinizing compounded GLP-1 drugs, raising concerns among doctors about potential health risks.
Researchers investigating 6,000 existing medications have identified potential links between common drugs and slowed biological aging.
Medical experts are raising alarms over the risk of muscle loss and increased frailty in older adults using GLP-1 weight loss medications.
Rapid growth in GLP-1 drug adoption is sparking new discussions on side effects, lifestyle requirements, and the social dilemmas of disclosure.
GLP-1 weight loss drugs are being used by a record number of Americans.
Medical professionals are warning that GLP-1 drugs and other common medications can increase health risks during current heat waves.
Researchers and doctors are exploring the broader implications of GLP-1 weight loss drugs as their use becomes more widespread.
Starting July 1, 2026, Medicare will cover GLP-1 weight-loss drugs for seniors, marking a significant expansion in obesity treatment access.
Employers are reconsidering coverage for popular GLP-1 weight loss drugs, leaving patients and insurers in limbo.
New research indicates that GLP-1 receptor agonists, including Ozempic, are being misused by individuals with eating disorders.
Ozempic users report unexpected changes in their sense of smell and taste.
Medicare's new pilot program expands access to GLP-1 drugs, sparking coverage on eligibility and potential impacts.